Autologous Anti-CD19 T-cell Receptor Fusion Construct T-cells TC-110

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, the autologous anti-CD19 TCR fusion construct (TRuC) T-cells TC-110 specifically target and bind to CD19-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. Compared to chimeric antigen receptor (CAR) T-cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy.

**Synonyms:** - Autologous Anti-CD19 TRuC T-cells TC-110 - CD19-specific Epsilon-TRuC TC-110 - CD19-specific T Cell Receptor Fusion Construct T cell TC-110 - TC 110 - TC 110 T Cells - TC-110 - TC-110 T Cells - TC110 - TC110 T Cells - TRuC T Cells TC-110 - TRuC-T Cell-targeting CD19 TC-110